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Background: Cabazitaxel is approved in patients with metastatic hormone-refractory prostate cancer previously
treated with a docetaxel-containing regimen. This study evaluated a weekly cabazitaxel dosing regimen. Primary
objectives were to report dose-limiting toxicities (DLTs) and to determine the maximum tolerated dose (MTD).
Efficacy, safety and pharmacokinetics were secondary objectives.
Methods: Cabazitaxel was administered weekly (1-hour intravenous infusion at 1.5–12 mg/m2 doses) for the first
4 weeks of a 5-week cycle in patients with solid tumours. Monitoring of DLTs was used to determine the MTD and
the recommended weekly dose.
Results: Thirty-one patients were enrolled. Two of six patients experienced DLTs at 12 mg/m2, which was declared
the MTD. Gastrointestinal disorders were the most common adverse event. Eight patients developed neutropenia
(three ≥ Grade 3); one occurrence of febrile neutropenia was reported. There were two partial responses (in breast
cancer) and 13 patients had stable disease (median duration of 3.3 months). Increases in Cmax and AUC0–t were
dose proportional for the 6–12 mg/m2 doses.
Conclusion: The MTD of weekly cabazitaxel was 12 mg/m2 and the recommended weekly dose was 10 mg/m2.
The observed safety profile and antitumour activity of cabazitaxel were consistent with those observed with other
taxanes in similar dosing regimens.
Trial registration: The study was registered with ClinicalTrials.gov as NCT01755390.
Keywords: Phase I, Cabazitaxel, Solid tumourBackground
Taxanes (including docetaxel and paclitaxel) are used
extensively in the treatment of solid malignancies [1].
Although taxane-based therapy is associated with fa-
vourable antitumour activity, constitutive and acquired
resistance limits its use [2]. Therefore, novel taxane-
based therapies that demonstrate antitumour activity in
taxane-resistant cancers are needed to extend patient
survival.
Cabazitaxel is a second-generation microtubule-sta-
bilising taxane that binds to tubulin and has a broad* Correspondence: pfumoleau@cgfl.fr
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reproduction in any medium, provided the orspectrum of antitumour activity, including tumours poorly
sensitive, or not sensitive, to docetaxel [3].
Preclinical studies have demonstrated that cabazitaxel
has comparable activity to docetaxel in an array of
docetaxel-sensitive cell lines, and efficacy in docetaxel-
resistant cell lines [3]. Preclinical studies have also
shown that cabazitaxel has antitumour activity against a
large spectrum of murine and human tumours [4-6].
Furthermore, in animal models, cabazitaxel was able to
cross the blood–brain barrier, as evidenced by efficacy
against intracranial xenografts [3,7]. Promising results in
preclinical studies were confirmed in early-phase clinical
studies that demonstrated that cabazitaxel has a man-
ageable toxicity profile as well as antitumour activity in a
range of solid tumours, including those progressing
under taxane-based therapy [8-10]. In addition, resultsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demonstrated that, compared with mitoxantrone, caba-
zitaxel improved survival in patients with metastatic
castration-resistant prostate cancer (mCRPC) who had
previously received docetaxel [11]. Cabazitaxel (25 mg/m2
once every 3 weeks) plus prednisone has been approved
by the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA), as well as by numer-
ous health authorities worldwide for the treatment of men
with hormone refractory metastatic prostate cancer (more
recently known as mCRPC) previously treated with a
docetaxel-containing regimen [12,13]. Additional dos-
ing schedules and treatment combination regimens
with cabazitaxel in a variety of tumours are also being
investigated.
The primary objectives of this study were to determine
the maximum tolerated dose (MTD) and dose-limiting
toxicities (DLTs) of cabazitaxel when given as a weekly
1-hour intravenous (IV) infusion for the first four con-
secutive weeks of a 5-week treatment cycle. Secondary
objectives were to establish the safety and pharmacoki-
netic (PK) profiles of cabazitaxel, to evaluate efficacy and
to inform the recommended dose and time interval for
future development.
Methods
Eligibility and patient characteristics
The study included patients (18–70 years of age) with
progressive, histologically proven, advanced neoplastic
disease that was either refractory to conventional treat-
ment or for which no standard therapy existed. Patients
were required to have adequate organ function, a life ex-
pectancy of ≥ 12 weeks and Eastern Cooperative On-
cology Group performance status 0–2. Prior therapies
were permitted providing they had been terminated a
minimum of 4 weeks prior to the start of the study
(depending on the therapy), and the patient had fully
recovered from any toxic effects of treatment. Prior pac-
litaxel and/or docetaxel treatment was permitted provid-
ing there was no residual evidence of taxane toxicity
(exceptions included alopecia [any grade] or peripheral
neuropathy [not exceeding Grade 1]).
Patients with haematological malignancies or symptom-
atic brain metastases were ineligible, as were pregnant or
lactating women and those receiving concurrent treatment
with other experimental drugs, any anticancer therapy or
corticosteroids (unless as chronic treatment). Patients were
also ineligible if they had another serious medical condition,
current peripheral neuropathy of any origin or a history
of severe allergic reaction to docetaxel or paclitaxel.
Patients who had received previous extensive radio-
therapy (> 20% of bone marrow area), prior intensive
therapy with autologous stem cell rescue, more than
two prior chemotherapy regimens for advanced diseaseor more than two regimens containing mitomycin C or
nitrosoureas were also excluded from the study.
The study was conducted according to the Declaration
of Helsinki (Somerset West Amendment, October 1996)
and in compliance with all local regulations. Written in-
formed consent was obtained from patients prior to the
initiation of any protocol-specific procedure. The proto-
col was approved by two independent Ethics Commit-
tees; Comité Consultatif de protection des personnes
dans la Recherche, Biomedical No. 2, Cellule de Promo-
tion, Immeuble Deurbroucq, 5 allée de l’Île Gloriette,
44093 Nantes, France (Chairperson Dr D. Duveau) and
Comité Ético de Investigación Clínica, Ciudad sanitaria
Vall d‘Hebrón, 08035 Barcelona, Spain (Chairperson Dr J.
B. Montoro-Ronsano).
Study design
The study was a two-centre, open-label, single-arm, dose-
finding study of cabazitaxel given as a weekly 1-hour IV
infusion to adult patients with advanced solid tumours.
The dose escalation protocol was based on the Simon 4A
design [14] without intrapatient dose escalation.
Toxicity was graded according to The National Cancer
Institute Common Toxicity Criteria (NCI-CTC, version
2.0) [15]. Non-dose-limiting toxicities (non-DLTs) were
defined as Grade 2–4 haematological toxicity (excluding
neutropenia Grade 4 for > 5 days, Grade 4 neutropenia
with fever for ≥ 1 day or Grade 4 thrombocytopenia) or
Grade 2 non-haematological toxicity (excluding alopecia,
nausea, vomiting and hypersensitivity). DLTs were de-
fined as Grade 4 neutropenia (absolute neutrophil
count < 0.5 × 109/l) lasting more than 5 days, Grade 4
thrombocytopenia (platelet count < 10 × 109/l), febrile
neutropenia (Grade 4 neutropenia with fever ≥ 38.5°C
[single elevation in oral temperature]) or Grade 3 or 4
non-haematological toxicity (excluding alopecia, nausea,
vomiting and hypersensitivity).
Selection of doses in the study
A dose of 1.5 mg/m2, which corresponds to one-tenth
of the severely toxic dose in 10% of mice, was chosen
as the starting dose. Eight dose levels were planned
(1.5, 2.1, 3, 4.2, 6, 8.4, 10 and 12 mg/m2). Of note, the
10 mg/m2 dose level was added as a protocol amend-
ment. At the first cycle, one patient per dose level was
to be included until a non-DLT or DLT was observed. If
the patient did not experience a non-DLT or DLT, a
double-step (100%) dose increment was allowed. If any
patient experienced a non-DLT at the first cycle, at least
three patients were to be included at the dose level at
which it occurred, with a single-step (40%) dose incre-
ment permitted if no DLT occurred among these three
patients. If any patient exhibited a DLT at a given dose
level, a total of at least six patients had to be included at
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made in the case of a DLT. The replacement of patients
who were not eligible or evaluable was permitted during
the first cycle. Patients who had withdrawn from the
study were not re-included.
The MTD was defined as the dose at which two or
more of three or six patients developed a DLT in the
first cycle of therapy. The recommended dose was de-
fined as one dose level below the MTD.Drug administration
Patients were hospitalised for 24 hours during their first
cabazitaxel administration. Blood pressure and heart rate
were monitored immediately before, during and after ad-
ministration. Cabazitaxel was administered as a 1-hour
IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle
until there was evidence of disease progression, un-
acceptable toxicity or the patient withdrew. No therapy
was administered in the last week of the treatment cycle.
Premedication was not required in this study.Safety evaluation
Patients were evaluable for safety if they started at least
one infusion of cabazitaxel and were not lost to follow-
up after the first infusion.
All enrolled patients underwent a complete health
evaluation at least 7 days before treatment commenced.
On the day of cabazitaxel administration, patients were
evaluated to ensure baseline characteristics were within
safe limits (absolute neutrophil count ≥ 1.0 × 109/l; plate-
let count ≥ 75 × 109/l; recovery of all prior severe [Grade
3–4] non-haematological toxicities; alanine aminotrans-
ferase/alkaline phosphatase/aspartate aminotransferase
≤Grade 1; and total bilirubin/serum creatinine within
normal limits). The duration of a cycle was 5 weeks, but
the interval between two cycles could be extended to
6 weeks (i.e. 1 week delay between cycles). If such a
delay occurred, patients were required to demonstrate
absolute neutrophil count ≥ 1.5 × 109/l and platelet
count ≥ 100 × 109/l, in addition to the above parameters,
prior to reinitiation of treatment. If recovery from the
previous cycle did not occur within 3 weeks, patients
were removed from the study. Additionally, during ther-
apy, neurological, toxicity and general health checks
were performed every week, and a cardiology examin-
ation (electrocardiogram, with Holter scan if patients
showed evidence of clinical dysrythmias) was conducted
before the start of the trial, every 5 weeks thereafter, and
again 3–4 weeks after the last infusion of study drug.
Biochemistry monitoring was performed on Days 1, 3, 7,
14, 21 and 28. All safety evaluations were repeated 3–
4 weeks after the last infusion to identify late-onset
adverse events.Concomitant medication was allowed in the case of
anaphylactic or hypersensitivity reaction, fluid reten-
tion or diarrhoea. Furthermore, curative use of colony-
stimulating factors was permitted provided that patients
demonstrated clinical evidence of neutropenic infection.Efficacy evaluation
An assessment of efficacy (according to RECIST criteria)
was conducted in patients who received at least one
treatment cycle, had at least one follow-up tumour as-
sessment and had no major on-study protocol devia-
tions. Efficacy endpoints were best overall response
(defined as the rate of complete and partial response,
recorded from the start of treatment until disease pro-
gression), duration of response, time to progression and
overall survival.
Response was assessed via independently reviewed
X-ray, ultrasound and computed tomography scans of
all uni- or bi-dimensionally measurable lesions. The
presence of measurable lesions was not a requirement of
the study.Pharmacokinetic analysis
Blood samples (3 ml) were collected from all patients for
assessments during cycles 1 and 2. Sampling was per-
formed on Days 1 and 22 at 5, 15, 30 and 60 minutes
and 2, 4, 6, 10, 24, 48 and 72 hours post-infusion. In
addition, samples were taken immediately prior to infu-
sion and at 30 and 55 minutes during the infusion on
Days 1 and 22 (cycle 1). Cerebrospinal fluid (CSF;
1.5 ml) and plasma samples (3 ml) were collected
15 minutes post-infusion when possible. Cabazitaxel
levels in plasma and CSF were measured using a vali-
dated liquid chromatography/tandem mass spectrome-
try method [16].
Accuracy, defined as the percentage difference bet-
ween the nominal and the mean measured concentra-
tions of quality controls, ranged from −4.1% (n = 74) to
6.4% (n = 75) during the analysis period. The precision
of the assay, established by the coefficients of variation
(CVs) of the quality controls, ranged from 9.9% to 14%
during the analysis period, and the accuracy of the dilu-
tion controls (1:2 or 1:4) was −4.2% (n = 18), with an as-
sociated precision of 3.4%.
PK analysis was carried out using WinNonlin software,
version 3.3 (Pharsight, USA). The calculation of PK
parameters was performed by a non-compartmental ana-
lysis. The maximum observed plasma concentration
(Cmax) and area under the plasma concentration–time
curve (AUC) from time 0 to the time of the last measur-
able concentration (AUC0–t) were determined. Accumula-
tion ratios were estimated at cycles 1 and 2 (Cmax Day 22/
Cmax Day 1 and AUC0–t Day 22/AUC0–t Day 1).
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Statistics were analysed using UNIX® with SAS® software,
Version 6.12 (SAS Institute, USA). Descriptive statistics
were provided by initial planned dose (safety- and
efficacy-evaluable patients) and overall dose level (safety
only). Furthermore, safety analyses were performed by
patient (worst grade under treatment or during follow-
up), by cycle (worst grade or acute adverse events) and
at first cycle (worst grade). Kaplan–Meier estimates
were performed to analyse censored data in the effi-
cacy population.
Descriptive statistics were reported for each PK param-
eter by dose level; the dose proportionality of the exposure
was assessed on AUC0–t and Cmax after dose normali-
sation using the Proc GLM procedure of SAS software
(Version 8.2; SAS Institute, USA). A test of linearity was
applied on the parameters Cmax and AUC0–t against the
dose expressed in mg/m2 followed by the Proc REG pro-
cedure of SAS software. The effect of the day (Day 22
versus Day 1) or the cycle (cycle 2 versus cycle 1) on the
exposure (Cmax and AUC0-t) after dose normalisation and
log transformation was assessed using a Proc MIXED pro-
cedure of SAS software with the patient taken as random
effect and with day and cycle as fixed effects.Table 1 Patient baseline characteristics
Plan
1.5 3
(n = 1) (n = 1) (n
Age, years, median (range) – – 4
(67–67) (36–36) (39
Male, n (%) 1 (100) 0 1 (
Caucasian, n (%) 1 (100) 1 (100) 4 (
ECOG performance status, n (%)
0 1 (100) – 1 (
1 – – 3 (
2 – 1 (100)
Tumour type, n (%)
Breast NA NA N
Ovary NA NA N
Stomach NA NA N
Small bowel NA NA N
Other NA NA N
Prior anticancer therapy, n (%)
Chemotherapy only – –
Immunotherapy* – –
Surgery only 1 (100) –
Combination therapy – 1 (100) 4 (
* Immunotherapy + biological markers. NA not available.Results
Patient characteristics
Thirty-one patients were enrolled; all were evaluable for
safety, and 27 were evaluable for tumour response. All
patients who received at least one administration of
cabazitaxel were included in these analyses. Baseline pa-
tient and disease characteristics are summarised in
Table 1.Treatment exposure, delays and dose reductions
The median number of cycles (all dose levels combined)
was two (range: 1–9 cycles) and the combined median
relative dose intensity was 100%. Median relative dose
intensity was not reported for the 1.5 and 3 mg/m2 dose
levels, because only one and two patients were enrolled,
respectively. The median relative dose intensity for the
remaining dose levels was 99%, 100%, 100% and 91% for
6, 8.4, 10 and 12 mg/m2, respectively. With all dose
levels included, median relative dose intensity was 100%.
The median cumulative dose was 46.7 mg/m2 (range:
6.0–297.8 mg/m2). Four cycles were administered at a
reduced dose due to non-haematological toxicities (8.4
and 12 mg/m2 dose level).ned dose level, mg/m2
6 8.4 10 12 Total
= 4) (n = 12) (n = 7) (n = 6) (N = 31)
8 52 44 55 51
–51) (35–69) (31–65) (34–70) (31–70)
25.0) 2 (16.7) 3 (42.9) 2 (33.3) 9 (29.0)
100) 12 (100) 7 (100) 6 (100) 31 (100)
25.0) 2 (16.7) 4 (57.1) 4 (66.7) 12 (38.7)
75.0) 9 (75.0) 2 (28.6) 2 (33.3) 16 (51.6)
– 1 (8.3) 1 (14.3) – 3 (9.7)
A NA NA NA 13 (41.9)
A NA NA NA 3 (9.7)
A NA NA NA 3 (9.7)
A NA NA NA 2 (6.5)
A NA NA NA 10 (32.3)
– 1 (8.3) – – 1 (3.2)
– – 1 (14.3) – 1 (3.2)
– – – – 1 (3.2)
100) 11 (91.7) 6 (85.7) 6 (100) 28 (90.3)
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No patients at the 1.5, 3, 6 or 8.4 mg/m2 dose levels ex-
perienced any DLT at the first cycle. Two of the six pa-
tients who received the 12 mg/m2 dose experienced
DLTs (Table 2) (both Grade 3 diarrhoea, including one
serious event leading to study discontinuation); as a re-
sult, the MTD was reached at 12 mg/m2. As per the
original protocol, 8.4 mg/m2 was initially deemed the
recommended IV dose. However, the protocol was sub-
sequently amended to include a dose level of 10 mg/m2,
an intermediate dose level between the recommended
IV dose of 8.4 mg/m2 and the MTD of 12 mg/m2. At
the point of the amendment, 11 patients had already
been enrolled and treated at the 8.4 mg/m2 dose level;
five patients in the dose-escalation phase (three as per
protocol, plus two who were waiting for the next dose
level to be released) and a further six patients to confirm
8.4 mg/m2 as the recommended dose. At the end of the
study, a patient who had been planned to receive the
10 mg/m2 dose was enrolled at the 8.4 mg/m2 dose. This
information accounts for the greater number of patients
in the 8.4 mg/m2 group compared with the 10 mg/m2
group.
One of the seven patients treated with the 10 mg/m2
dose experienced a DLT (Grade 3 diarrhoea). Therefore,
10 mg/m2 was defined as the revised recommended IV
(weekly) dose for further clinical investigations.
Safety
The most frequently reported non-haematological ad-
verse events regardless of relationship to study drugTable 2 Dose-limiting toxicities at cycle 1 and adverse
events at subsequent cycles
DLTs at the first cycle (n = 3)
Dose level, mg/m2 Patients, n Event
8.4 – –
10 1 Grade 3 diarrhoea
12 2 Grade 3 diarrhoea (both patients)
Adverse events at cycles ≥ 2 (n = 13)
Dose level, mg/m2 Patients, n Event
8.4 4 Grade 3 asthenia (three patients)
Grade 3 diarrhoea
10 1 Grade 3 haematuria
Grade 3 dysuria
12 3 Grade 3 asthenia (two patients)
Febrile neutropenia
Neutropenia Grade 4 for > 5 days
(two patients)
Grade 3 diarrhoea
Grade 3 astheniaincluded pain (97%, most of which was tumour-related
[77.4%]), gastrointestinal toxicities (81%, mostly diar-
rhoea [52%]), fatigue (68%), sensory neuropathy (36%, of
which 26% was Grade 1 and 10% was Grade 2), alopecia
(19%) and peripheral oedema (16%). Severe liver to-
xicities were reported in two patients (one patient with
Grade 3 alkaline phosphatase and Grade 3 gammagluta-
myl transferase at cycle 1 and one patient with Grade 3 al-
kaline phosphatase at cycle 3); both patients withdrew
from the study due to progressive disease. Overall, neutro-
penia was reported in eight patients. Two patients experi-
enced Grade 4 neutropenia (both received 12 mg/m2) and
one patient experienced Grade 3 neutropenia (8.4 mg/m2
dose level). Febrile neutropenia was observed in one pa-
tient (Table 3). The median time to neutrophil nadir was
22 days (range: 17–32 days) and 74% of patients com-
pleted their treatment without neutropenic complications.
Neutrophil nadir was not dose dependent. Anaemia was
frequent but only one patient developed Grade 4 toxicity
at 8.4 mg/m2.
Eight patients experienced adverse events possibly re-
lated to the study drug. The most frequently reported in-
cluded fatigue (45%), diarrhoea (39%) and nausea (32%).
Five serious adverse events (diarrhoea, dysuria/haema-
turia, febrile neutropenia and peripheral oedema) were
reported in four patients; all occurred at the 10 and
12 mg/m2 dose levels. Eight out of 31 patients (26%)
were withdrawn from the study because of adverse
events, although in two of these patients the adverse
events were probably not related to the study drug. Fif-
teen deaths were reported and progressive disease was
the cause of all but one death, which resulted from pneu-
monia that was not deemed to be related to cabazitaxel
administration.
Efficacy
Of the 31 patients treated, 27 were evaluable for re-
sponse. There were two confirmed partial responses at
8.4 and 12 mg/m2; both patients had breast cancer. A
third patient had an unconfirmed partial response. In
addition, 13 patients had stable disease (median duration
of 3.3 months) and 11 had progressive disease (Table 4).
The duration of the two partial responses was 5+ and 2+
months (8.4 and 12 mg/m2, respectively) from first infu-
sion to censored date. The median time to progression
was 2.1 months (95% confidence interval 0.99–3.22;
range: 0–10.4 months), although six patients were
censored (five for further antitumour therapy and one
lost during follow-up). Median overall survival was
15.6 months (range: 0.99–32.7 months).
Pharmacokinetics
PK evaluation was carried out in 31 patients during the
first two cycles. After the first administration of 10 mg/m2
Table 3 Adverse events related to the study drug (all cycles)
Planned dose level, mg/m2 All
(N = 31)
1.5 3 6 8.4 10 12
(n = 1) (n = 1) (n = 4) (n = 12) (n = 7) (n = 6)
Adverse event, n G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4 G3 G4
Non-haematological
Fatigue – – – – – – 3 – – – 2 – 5 –
Diarrhoea – – – – – – 1 – 1 – 3 – 5 –
Haematuria – – – – – – – – 1 – – – 1 –
Febrile neutropenia – – – – – – – – – – 1 – 1 –
Dysuria – – – – – – – – 1 – – – 1 –
Haematological
Neutropenia – – – – – – 1 – – – – 2 1 2
Anaemia – – – – – – – 1 – – – – – 1
Days to neutrophil nadir, median (range) – – – 17 – – 22
– 32–32 31–31 17–22 18–18 21–22 17–32
Median neutrophil nadir, x 109/l (range) – – 2.3 2.2 2.2 3.1 2.3
(3.4–3.4) (1.8–1.8) (1.4–9.0) (0.9–5.0) (1.2–5.7) (0.2–7.3) (0.2–9.0)
G3 Grade 3, G4 Grade 4.
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73 hours after the end of infusion in the four patients for
whom PK evaluation was possible. After the fourth in-
fusion, cabazitaxel was detectable up to 10 hours (one
patient), 48 hours (one patient) and 72–74 hours (two pa-
tients) after the end of infusion in the four patients for
whom PK evaluation was possible. The PK parameters of
cabazitaxel are shown in Table 5. The increase in Cmax
and AUC0–t after the first administration in cycle 1
appeared dose-proportional from 1.5–12 mg/m2. Follow-
ing exclusion of the patients treated at 1.5 and 3 mg/m2
(n = 1 each), statistical analysis confirmed that Cmax and
AUC0–t were dose-proportional from 6–12 mg/m
2
(Figure 1). There was a significant increase (41%;
p = 0.0016) in AUC0–t on Day 22 compared with Day 1
(both cycle 1). However, Cmax remained unchanged com-
pared with Day 1. Furthermore, there were no statistical
differences in Cmax and AUC0–t between cycles 1 and 2 on










8.4 PR PR PR
PR NC NC
10 NCb NCc NCc
12 PR PR PR
a Each response represents one patient. b CR at cycle 2. c PR at cycle 2.
CR complete response, PR partial response, NC no change.quantification, 1 μg/l) in four samples of CSF collected up
to 35 minutes after the end of infusion in three patients
receiving 3 mg/m2 and 6 mg/m2 doses. Low (≤ 14.4 μg/l)
concomitant plasma concentrations of cabazitaxel were
reported in two patients (one taken 3 minutes and one
taken 5 minutes prior to lumbar puncture).
Discussion
Cabazitaxel is a second-generation taxane that has dem-
onstrated efficacy against taxane-resistant tumours in
both in vitro and in vivo models [3-6,9-11,17]. Preclinical
studies reported that intermittent dosing schedules (vs
split-dose schedules) allowed the highest dose of caba-
zitaxel to be administered with the best patient recovery
and optimum antitumour activity [18]. In addition, pre-
vious animal studies indicated that the efficacy and
toxicity of cabazitaxel are schedule-dependent [5]. There-
fore, this study was designed to assess DLTs and the MTD
(and thus the recommended dose) of a weekly dosing regi-
men, with patients receiving cabazitaxel weekly for the
first 4 weeks of a 5-week treatment cycle. These results
provided the basis for the 5-week treatment cycle de-
scribed here. Thirty-one patients were enrolled in this
Phase I dose-finding study. Investigation of the PK, and
safety profiles and efficacy of cabazitaxel were secondary
objectives.
The MTD for weekly administration without pre-
medication was established as 12 mg/m2; 10 mg/m2 was
the dose recommended for future clinical studies using a
weekly dosing regimen. There have been several studies
Table 5 Pharmacokinetic parameters of cabazitaxel on Days 1 and 22 (cycle 1)
Day 1 Day 22
Dose, mg/m2 Patients treated/
with data
Cmax,
a μg/l AUC0–t, μg.h/l Patients treated/
with data
Cmax,
a μg/l AUC0–t, μg.h/l
1.5 1/1 15.5 17.2 1/1 13.5 28.2
3 1/1 41.9 47.1 1/1 23.0 102
6 4/3 31.2 ± 15.5 (50) 89.7 ± 51.8 (58) 4/3 49.4 ± 13.8 (28) 150 ± 34 (22)
8.4 12/11 71.7 ± 54.4 (76) 144 ± 46 (32) 11/9 70 ± 30.4 (43) 190 ± 89 (47)
10 7/4 102 ± 52 (51) 153 ± 91 (60) 4/4 89.3 ± 80.6 (90) 187 ± 56 (30)
12 6/3 152 ± 148 (97) 212 ± 120 (56) 4/2 84.8–480 145–447
Data are expressed as mean ± SD (CV%).
a Observed value at 5 minutes before the end of infusion except for four patients on Days 1 and for seven patients on Day 22 for whom maximal plasma
concentrations were measured 20 minutes before the end of infusion.
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mostly with a 3-weekly administration schedule [8-11].
The results of these studies, conducted contemporan-
eously with the current study, provide some evidence
that a 3-weekly dosing schedule may be associated with
more favourable toxicity and efficacy profiles compared
with a weekly regimen. They also reported different
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y = 20.165x – 95.734
R2 = 0.2338




Figure 1 Cabazitaxel pharmacokinetics. (a) Cmax versus dose and
(b) AUC0–t versus dose at the first administration at cycle 1 (n = 21).explored the use of cabazitaxel in advanced solid tumours
and recommended a 20 mg/m2 dose, whereas a similarly
designed Phase I study recommended a 25 mg/m2 dose
for future studies [8]. Further evaluation of 3-weekly dos-
ing was carried out in a Phase II study in patients with
metastatic breast cancer, in which patients received
20 mg/m2, with escalation to 25 mg/m2 if no significant
adverse event was observed at cycle 1 [10]. The study
reported promising efficacy results, with two complete
and eight partial responses. The results from the 3-weekly
Phase I and Phase II trials informed the design of the
Phase III TROPIC (NCT00417079) trial of cabazitaxel in
combination with prednisone in patients with mCRPC
previously treated with a docetaxel-containing regimen
[8,9]. This pivotal trial was the basis for the approval by
the FDA and EMA of cabazitaxel in combination with
prednisone in that patient population [12,13]. A trial com-
paring 20 mg/m2 and 25 mg/m2 doses of cabazitaxel in a
head-to-head study in patients with mCRPC is ongoing.
In this study, the median relative dose intensity was
100% across all dose levels, resulting in an absolute. The
dose intensity of 10 mg/m2/week (3-weekly regimen)
was one of several dose levels assessed in a previous
Phase I; median relative dose intensity was similar to
that reported here [9]. Furthermore, in the pivotal Phase
III TROPIC study, in which the approved regimen
(25 mg/m2 once every 3 weeks) was used, the absolute
dose intensity was slightly lower, at 8.3 mg/m2/week
(relative dose intensity 96.1%) compared with the results
shown here with a lower dose [11].
In the current study, cabazitaxel given on a weekly
schedule appeared to be tolerable with a manageable
side-effect profile, despite the fact that cabazitaxel was
administered without premedication. Notable toxicities
reported in this study included both neutropenia and
diarrhoea, which are consistent and predictable side
effects of taxane-based therapy. The most common
Grade ≥ 3 toxicities were fatigue and diarrhoea. The tox-
icity results presented here are similar to, but with lower
incidence rates than, those reported in the TROPIC trial,
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schedule [11]. Analyses of results from the TROPIC trial
demonstrated that these adverse events can be appro-
priately managed with proactive treatment and con-
scientious monitoring. Specifically, prophylactic use of
granulocyte colony-stimulating factor reduced the sever-
ity of neutropenia in patients receiving cabazitaxel plus
prednisone [19], and diarrhoea was resolved with sup-
portive treatment.
The efficacy results presented from the current Phase
I study are consistent with those observed in other
cabazitaxel studies with other schedules of administra-
tion, demonstrating the activity of the agent against a
variety of solid tumours in patients who have received
prior anticancer therapy [9,10]. Indeed, in this study,
over half of the patients experienced either stabilised or
improved responses, despite the advanced nature of their
disease. Furthermore, in the dose-escalation part of the
study, treatment with cabazitaxel resulted in median
overall survival of 15.6 months and a median time to
progression of 2.1 months. It is notable that Phase III
studies with docetaxel in prostate cancer have demon-
strated that a weekly regimen may be associated with in-
ferior efficacy to a 3-weekly regimen [20]. Based on
these data, it is unlikely that a weekly regimen of
cabazitaxel in patients with prostate cancer will progress
to Phase III trials.
Available data indicate that cabazitaxel PK appears to
be dose proportional. Population analyses carried out on
pooled PK data, from Phase I, II and III studies, in-
cluding cabazitaxel plasma concentrations obtained after
the first administration in patients treated at 10 or
12 mg/m2 from this study, facilitated the estimation of
half-lives, clearance (CL) and volume of distribution at
steady state (Vss). PK parameters from this study gener-
ated in the pooled analysis (mean CL: 25.5 l/h/m2; CV:
36%, mean elimination half-life: 130 hours; CV: 72% and
mean Vss; 3160 l/m
2; CV: 66%) were in the range of
those estimated in patients with solid tumours or with
mCRPC treated using the 3-weekly schedule [16], in-
dicating no marked difference between weekly and
3-weekly regimens.
Consistent with the long elimination half-life, some
accumulation in the deep distribution compartment
appeared to occur after the fourth administration (within
cycle 1) of cabazitaxel, with a significant increase in ex-
posure (AUC0-t). However, no difference in exposure
was observed between the first administrations of cycles
1 and 2, suggesting that a 2-week treatment break after
4-weekly administrations can avoid the accumulation
of cabazitaxel in the plasma, making a weekly admin-
istration regimen feasible. As cabazitaxel is able to
cross the blood–brain barrier in animals [3,7], four
lumbar punctures were undertaken to evaluate cabazitaxelpenetration in this study; cabazitaxel was not detected
in any CSF samples. However, the negative results do
not conclusively demonstrate that cabazitaxel does not
enter the CSF, as levels in plasma samples taken within
5 minutes of lumbar puncture were low (≤ 14.4 ng/ml),
all four patients had received low doses of cabazitaxel
(3–6 mg/m2) and a prior study has demonstrated low
(8%) free fraction of cabazitaxel in the plasma [8].
Taken together, the results presented here suggest
that weekly dosing at the recommended dose of
10 mg/m2 may be a feasible treatment regimen in pa-
tients with solid tumours. While this regimen is not
actively being pursued at this time, other studies
evaluating the efficacy of different cabazitaxel doses,
alone or in combination with other anticancer agents
or radiotherapy, in a range of solid tumours, are cur-
rently planned or ongoing.Conclusions
The MTD of weekly cabazitaxel was 12 mg/m2 and the
recommended dose for weekly cabazitaxel was 10 mg/m2.
The adverse events observed were consistent with other
taxanes in similar dosing regimens. Antitumour activi-
ty was also comparable with other taxanes in similar
dosing regimens. PK results showed that Cmax and
AUC0–t were dose proportional. In conclusion, this
study demonstrates promising results with a cabazi-
taxel weekly dosing regimen, which may provide the
foundation for future studies.
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